What Is the CNPV Program?
A first-of-its-kind FDA pilot designed to dramatically accelerate review times—from the typical 6+ months down to 1–2 months— for products that address critical national health priorities.
The program maintains full FDA safety, efficacy, and scientific standards while removing procedural delays that slow access to high-impact therapies.
Why the CNPV Program Matters
- Strengthens U.S. drug supply chain by prioritizing domestic manufacturing of essential medicines.
- Accelerates access to breakthrough therapies in cancer, diabetes, infertility, sensory loss, addiction treatment, and more.
- Improves affordability by reducing development and review burdens for manufacturers.
- Uses multidisciplinary, tumor‐board–style review to ensure scientific rigor even on fast timelines.
- Voucher-based model provides accelerated review but is non-transferable, ensuring only true priority products benefit.
How It Works
01. Voucher Selection: Products are nominated internally or submitted externally, then evaluated based on
- Alignment with U.S. national health priorities
- Public health impact
- Readiness of clinical and manufacturing data
- Resource/timing feasibility
- Known risks or dependencies. Note: Receiving a voucher does not increase chances of
approval—only the speed of review.
02. Presubmission Phase: Sponsors collaborate with FDA to eliminate bottlenecks before filing
- CMC packages due 60+ days before final submission
- Early labeling reviews
- Rolling submissions to prevent review delays
03. Accelerated Review
- Applications undergo the FDAs full scientific assessment
- Senior leadership participates in multidisciplinary discussions
- Review timelines remain flexible to maintain scientific quality
- Some approvals have occurred in as little as 55 days
The First Wave of Prioritized Products 2026
The FDA has designated multiple high-value therapies across critical public health needs and multiple key approvals as of March 2026.
Strengthening U.S. Supply & Essential Medicines
- Augmentin XR – Rebuilding domestic antibiotic manufacturing – Approved
- Ketamine – Ensuring U.S. supply of a critical anesthesia drug
Transformational Therapies for Chronic & Rare Conditions
- Pergoveris – Infertility
- Teplizumab – Type 1 diabetes
- Bitopertin – Porphyria
- Wegovy HD – semaglutide injection for weight loss and long-term maintenance of weight loss – Approved
Oncology Breakthroughs
- Hernexeos (zongertinib) – Lung cancer – Approved
- Tec‐Dara (teclistamab + daratumumab) – Relapsed/ refractory multiple myeloma Approved just 55 days after filing
- RMC‐6236 – Pancreatic cancer
- Sacituzumab Tirumotecan – TROP2-directed ADC
Addressing Addiction, Sensory Loss & More
- Cytisinicline – Nicotine vaping addiction
- DB‐OTO – Genetic therapy for deafness
- Cenegermin‐bkbj – Vision restoration
- Enlicitide decanoate – Oral PCSK9 inhibitor for cholesterol management
Why This Pilot Signals a Major Shift
The CNPV program represents a new regulatory model—one where:
- Critical medicines get rapid, coordinated, senior-level attention
- Sponsors collaborate earlier and more deeply with FDA
- National health security becomes a central driver of regulatory priority
For patients, providers, manufacturers, and policymakers, CNPV marks a modernized, mission-focused FDA aiming to get the right products to the public faster and more reliably than ever before.
Ready to Evaluate Your Fit for the CNPV Program?
Connect with Syner-G today for a complimentary consultation.
Let s determine whether this accelerated pathway can advance your program and how to position your asset for maximum impact, speed, and success.
References:
https://www.fda.gov/news events/press announcements/fda grants third approval under national priority voucher program
https://www.fda.gov/industry/commissioners national priority voucher cnpv pilot program
https://www.fda.gov/media/190896/download?attachment
